Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “NSCLC MRD ctDNA”

22 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 22 results

Not applicableLooking for participantsNCT06198868
What this trial is testing

MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Jiangsu Cancer Institute & Hospital 60
Not applicableActive Not RecruitingNCT05219734
What this trial is testing

MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment

Who this might be right for
CancerSolid TumorNon Small Cell Lung Cancer+2 more
Invitae Corporation 400
Large-scale testing (Phase 3)Not Yet RecruitingNCT06323148
What this trial is testing

Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

Who this might be right for
Lung CancerEGFR Gene MutationMinimal Residual Disease
Fudan University 226
Not applicableNot Yet RecruitingNCT05822284
What this trial is testing

CtDNA-MRD in Stage IIIB-C NSCLC Patients Treated With Induction Chemoimmunotherapy

Who this might be right for
Non-small Cell Lung Cancer
Second Xiangya Hospital of Central South University 50
Not applicableNot Yet RecruitingNCT07689812
What this trial is testing

Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)NSCLC (Non-small Cell Lung Cancer)NSCLC (Non-small Cell Lung Carcinoma)+12 more
Natera, Inc. 920
Not applicableEnrolling By InvitationNCT05441566
What this trial is testing

Significance of MRD After Surgery in Driver Gene-positive and Driver Gene-negative Stage IB-IIA NSCLC

Who this might be right for
NSCLC MRD ctDNA
Shenzhen People's Hospital 60
Very early researchNot Yet RecruitingNCT06979661
What this trial is testing

Trial of ctDNA of Guidance to Determine PostOperative Radiation Therapy

Who this might be right for
Lung CancerNon Small Cell Lung CancerLung Cancer Recurrent
Rutgers, The State University of New Jersey 25
Not applicableLooking for participantsNCT04976296
What this trial is testing

MRD Monitoring in Lung Cancer After Resection

Who this might be right for
Lung Cancer
Guangdong Provincial People's Hospital 300
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07661173
What this trial is testing

A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Anhui Provincial Cancer Hospital 154
Testing effectiveness (Phase 2)Looking for participantsNCT05286957
What this trial is testing

MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC

Who this might be right for
NSCLC
The First Affiliated Hospital of Zhengzhou University 60
Testing effectiveness (Phase 2)Looking for participantsNCT06951646
What this trial is testing

CtDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

Who this might be right for
Non Small Cell Lung CancerImmune Checkpoint Inhibitors (ICIs)
Second Xiangya Hospital of Central South University 70
Early research (Phase 1)Study completedNCT04853017
What this trial is testing

ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

Who this might be right for
Minimal Residual DiseaseKRAS G12DKRAS G12R+9 more
Elicio Therapeutics 25
Not applicableLooking for participantsNCT07257471
What this trial is testing

Application Research of Methylation Markers in Early-stage Lung Cancer Patients Treated With Co-ablation System Therapy

Who this might be right for
Lung Cancer (NSCLC)
Beijing Haidian Hospital 30
Not applicableUnknownNCT05167604
What this trial is testing

Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell LungNext-Generation SequencingChemotherapy, Adjuvant+2 more
Tang-Du Hospital 150
Testing effectiveness (Phase 2)Looking for participantsNCT06426511
What this trial is testing

CtDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC

Who this might be right for
Lung Cancer, Nonsmall Cell
Sun Yat-sen University 80
Not applicableLooking for participantsNCT05965024
What this trial is testing

Exploration on the Value of MRD Based on ctDNA Detection in Predicting Recurrence of Resected Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China 377
Not applicableNot Yet RecruitingNCT06856798
What this trial is testing

Construction of a Prognostic and Prediction Model for Perioperative Immunotherapy in NSCLC: A Multi - Omics Perspective

Who this might be right for
NSCLC Stage IIIA/BNSCLC Stage II
Ziming Li 120
Not applicableLooking for participantsNCT07057102
What this trial is testing

Multiple Omics Sequencing Technologies in Predicting the Efficacy and Monitoring the Recurrence of Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 40
Not applicableActive Not RecruitingNCT05198154
What this trial is testing

CtDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLC

Who this might be right for
Advanced Lung Non-Small Cell Carcinoma
Fang Wu 100
Not applicableLooking for participantsNCT06924710
What this trial is testing

Adaptive Therapy for Resected Stage ⅠA2-Ⅱ NSCLC Patients With Undetectable MRD

Who this might be right for
NSCLC
Peking University Cancer Hospital & Institute 286
Next Page